23.06.2011SIB honours two young bioinformaticians for their outstanding research workYou are hereNewsSIB honours two young bioinformaticians for their outstanding research work
Yesterday during the 9th [BC]2 Computational Biology Conference in Basel, SIB Swiss Institute of Bioinformatics announced the two winners of the SIB Awards 2011.
The SIB Young Bioinformatician Award and the SIB Best Graduate Paper Award, respectively doted with a cash prize of CHF 10'000 and CHF 5’000, are given yearly by SIB to recognise two excellent young bioinformaticians. This year’s winners both belong to SIB’s Computational Systems Biology Lab Group led by Prof. Felix Naef at the EPFL (Swiss Federal Institute of Technology in Lausanne). Their outstanding research work offers new insights to medical research. Nacho Molina, winner of the Young Bioinformatician Award invented a computational methodology in the frame of a study on gene expression, whose findings can for instance help to understand why antibiotics never eradicate all bacteria and to optimise existing treatments. Guillaume Rey, winner of the Best Graduate Paper Award, studied the role of the organism’s internal clock - or circadian clock- in controlling the functions of the liver. His findings will allow to optimise medical treatment effectiveness basing on biological rhythms, in other words, in adapting them to times of the day when our bodies are the most receptive.
Mymetics SATherapeutics & Diagnostics, VaccinesMymetics Corporation (OTCQB: MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies.
Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.
Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath – Astellas). The company’s intra nasal Influenza vaccine and the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase.